Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen with minimal to no titration necessary ...
The MarketWatch News Department was not involved in the creation of this content. Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of ...
[SINGAPORE] Hin Leong founder Lim Oon Kuin was hospitalised with breathing difficulties just three days before the 84-year-old’s 13½-year prison sentence was due to start on Wednesday (Apr 1). His son ...
Planning a move to another town, city or state? The biggest factors in any move are the standard of living and what salary you’ll need to make in order to reach that standard. Our cost of living ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results